Abstract
Clostridium difficile has become the most common infectious cause of healthcare-associated diarrhea, with serious morbidity, prolonged hospitalization and even death. Treatment of the disease utilizing today’s therapies does not guarantee a successful outcome. In the past decade, many new ideas and inventions have surfaced exploring different treatment strategies of Clostridium difficile associated diarrhea (CDAD). These treatments include antitoxins, novel antimicrobials, immunoglobulins and large inert synthetic compounds. In this paper, we survey of a number of representative patents issued from 2000 to the present targeting treatment of this difficult and dreaded disease.
Keywords: Bacterial toxin, Clostridium difficile, drug target, patents.
Recent Patents on Anti-Infective Drug Discovery
Title:A Surview of Recent Patents on Anti-Infective Therapy for Clostridium difficile
Volume: 8 Issue: 2
Author(s): Germine S. Soliman, Bechoi Saleib and Stephen J. Scholand
Affiliation:
Keywords: Bacterial toxin, Clostridium difficile, drug target, patents.
Abstract: Clostridium difficile has become the most common infectious cause of healthcare-associated diarrhea, with serious morbidity, prolonged hospitalization and even death. Treatment of the disease utilizing today’s therapies does not guarantee a successful outcome. In the past decade, many new ideas and inventions have surfaced exploring different treatment strategies of Clostridium difficile associated diarrhea (CDAD). These treatments include antitoxins, novel antimicrobials, immunoglobulins and large inert synthetic compounds. In this paper, we survey of a number of representative patents issued from 2000 to the present targeting treatment of this difficult and dreaded disease.
Export Options
About this article
Cite this article as:
Soliman S. Germine, Saleib Bechoi and Scholand J. Stephen, A Surview of Recent Patents on Anti-Infective Therapy for Clostridium difficile, Recent Patents on Anti-Infective Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574891X113089990016
DOI https://dx.doi.org/10.2174/1574891X113089990016 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Fospropofol, A New Sedative Anesthetic, and Its Utility in the Perioperative Period
Current Pharmaceutical Design Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Flow Volumes of Internal Jugular Veins are Significantly Reduced in Patients with Cerebral Venous Sinus Thrombosis
Current Neurovascular Research Insights into Peptide Mediated Antibiofilm Treatment in Chronic Wound: A Bench to Bedside Approach
Current Protein & Peptide Science Effect of Direct-Acting Antiviral Drugs on Erectile Functions among Hepatitis C Patients: A Prospective Interventional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets Magnetic Resonance Contrast Media Sensing In Vivo Molecular Imaging Agents: An Overview
Current Radiopharmaceuticals Role of the Sympathetic Nervous Activity in Hypertension-Update in 2013
Current Hypertension Reviews Autophagy in Diabetic Retinopathy
Current Neuropharmacology Thrombus Extraction Catheters vs. Angiojet Rheolytic Thrombectomy in Thrombotic Lesions/SV Grafts
Current Cardiology Reviews Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Perinatal Management of Fetal Tumors
Current Pediatric Reviews The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery The Influence of DMPK as an Integrated Partner in Modern Drug Discovery
Current Drug Metabolism Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology ACE Inhibitors and ARBs for Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design